OBJECTIVE: To estimate the potential effect of the acceleration of administration of the first dose of pneumococcal conjugate vaccine from 2 months to 6 weeks of age. DESIGN: Prediction model using data from a retrospective cohort study. SETTING: Published data from 8 states that participated in Active Bacterial Core Surveillance of the Emerging Infections Program Network for pneumococcus before pneumococcal conjugate vaccine introduction (July 1, 1997- June 30, 2000). PARTICIPANTS: A total of 759 739 live births under surveillance. Intervention Estimating the potential benefit of administration of the first dose of the pneumococcal conjugate vaccine at 6 weeks of age instead of 2 months of age. MAIN OUTCOME MEASURES: Estimation of reduction in the rate of invasive pneumococcal disease in infants 61 to 90 days of age. RESULTS: The estimated direct effect of the acceleration of administration of the first dose of pneumococcal conjugate vaccine from 2 months to 6 weeks of age when this vaccine was first introduced could have reduced the burden of invasive pneumococcal disease in infants 61 to 90 days of age by 39.9%, 56.0%, and 72.1% for respective vaccine efficacies of 50%, 70%, and 90%. This translates into preventing an estimated 73, 103, and 133 cases of invasive pneumococcal disease per year among approximately 4 112 052 live births in the United States. CONCLUSIONS: The acceleration of administration of the pneumococcal conjugate vaccine from 2 months to 6 weeks of age could reduce the burden of invasive pneumococcal disease among infants. This observation may be important when a new conjugate vaccine becomes available, particularly among populations with prevalent invasive pneumococcal disease from a serotype included in the new vaccine.
OBJECTIVE: To estimate the potential effect of the acceleration of administration of the first dose of pneumococcal conjugate vaccine from 2 months to 6 weeks of age. DESIGN: Prediction model using data from a retrospective cohort study. SETTING: Published data from 8 states that participated in Active Bacterial Core Surveillance of the Emerging Infections Program Network for pneumococcus before pneumococcal conjugate vaccine introduction (July 1, 1997- June 30, 2000). PARTICIPANTS: A total of 759 739 live births under surveillance. Intervention Estimating the potential benefit of administration of the first dose of the pneumococcal conjugate vaccine at 6 weeks of age instead of 2 months of age. MAIN OUTCOME MEASURES: Estimation of reduction in the rate of invasive pneumococcal disease in infants 61 to 90 days of age. RESULTS: The estimated direct effect of the acceleration of administration of the first dose of pneumococcal conjugate vaccine from 2 months to 6 weeks of age when this vaccine was first introduced could have reduced the burden of invasive pneumococcal disease in infants 61 to 90 days of age by 39.9%, 56.0%, and 72.1% for respective vaccine efficacies of 50%, 70%, and 90%. This translates into preventing an estimated 73, 103, and 133 cases of invasive pneumococcal disease per year among approximately 4 112 052 live births in the United States. CONCLUSIONS: The acceleration of administration of the pneumococcal conjugate vaccine from 2 months to 6 weeks of age could reduce the burden of invasive pneumococcal disease among infants. This observation may be important when a new conjugate vaccine becomes available, particularly among populations with prevalent invasive pneumococcal disease from a serotype included in the new vaccine.
Authors: Peter G Szilagyi; Marie R Griffin; Laura P Shone; Richard Barth; Yuwei Zhu; Stanley Schaffer; Sandra Ambrose; Jason Roy; Katherine A Poehling; Kathryn M Edwards; Frances J Walker; Benjamin Schwartz Journal: Pediatrics Date: 2006-10 Impact factor: 7.124
Authors: Blanca E Gonzalez; Kristina G Hulten; Linda Lamberth; Sheldon L Kaplan; Edward O Mason Journal: Pediatr Infect Dis J Date: 2006-04 Impact factor: 2.129
Authors: Katherine A Poehling; Thomas R Talbot; Marie R Griffin; Allen S Craig; Cynthia G Whitney; Elizabeth Zell; Catherine A Lexau; Ann R Thomas; Lee H Harrison; Arthur L Reingold; James L Hadler; Monica M Farley; Bridget J Anderson; William Schaffner Journal: JAMA Date: 2006-04-12 Impact factor: 56.272
Authors: Cynthia G Whitney; Tamar Pilishvili; Monica M Farley; William Schaffner; Allen S Craig; Ruth Lynfield; Ann-Christine Nyquist; Kenneth A Gershman; Marietta Vazquez; Nancy M Bennett; Arthur Reingold; Ann Thomas; Mary P Glode; Elizabeth R Zell; James H Jorgensen; Bernard Beall; Anne Schuchat Journal: Lancet Date: 2006-10-28 Impact factor: 79.321
Authors: Thomas R Talbot; Katherine A Poehling; Tina V Hartert; Patrick G Arbogast; Natasha B Halasa; Ed Mitchel; William Schaffner; Allen S Craig; Kathryn M Edwards; Marie R Griffin Journal: Pediatr Infect Dis J Date: 2004-08 Impact factor: 2.129
Authors: Katherine A Poehling; Bonnie J Lafleur; Peter G Szilagyi; Kathryn M Edwards; Ed Mitchel; Richard Barth; Benjamin Schwartz; Marie R Griffin Journal: Pediatrics Date: 2004-09 Impact factor: 7.124
Authors: David A Bergman; Michelle L Mayer; Robert H Pantell; Stacia A Finch; Richard C Wasserman Journal: Pediatrics Date: 2006-03 Impact factor: 7.124
Authors: Robert H Pantell; Thomas B Newman; Jane Bernzweig; David A Bergman; John I Takayama; Mark Segal; Stacia A Finch; Richard C Wasserman Journal: JAMA Date: 2004-03-10 Impact factor: 56.272